Skip to main content

Table 5 The percentage of patients achieving treatment success or failure defined according to AQLQ change and exacerbations

From: Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

Category

AQLQ change from baseline at Week 52

Exacerbation

SAL/FP

n = 158

n (%)

FOR/BUD

n = 155

n (%)

Success

≥ 0.5

No

100 (63)

83 (53)

No change

>-0.5 – <0.5

No

36 (23)

40 (26)

Failure

  

22 (14)

32 (21)

 

≥ 0.5

Yes

12 (7)

17 (11)

 

>-0.5 – <0.5

Yes

4 (3)

7 (5)

 

≤ -0.5

No

4 (3)

3 (2)

 

≤ -0.5

Yes

2 (1)

5 (3)

  1. AQLQ = Asthma Quality of Life Questionnaire; FOR/BUD = formoterol/budesonide combination; SAL/FP = salmeterol/fluticasone propionate combination.